Our previous study indicated that pre-treatment TLR was a potent marker to predict pathological response of HCC patients (BCLC stage C) treated with Lenvatinib and PD-1 inhibitors as conversion therapy (33). Here, PDCD1 is linked to hepatocellular carcinoma.